New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
10:00 EDTZPIN, SRPT, PTCT, ENPH, WPG, QSII, NEP, CSG, TSE, QIWI, MTX, ATNM, ABY, AXYSOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Abengoa Yield (ABY) initiated with an Equal Weight at Morgan Stanley... Actinium Pharmaceuticals (ATNM) initiated with a Buy at Canaccord... Axys Technologies (AXYS) initiated with a Buy at Dougherty... Chambers Street Properties (CSG) initiated with a Neutral at SunTrust... Enphase Energy (ENPH) initiated with a Buy at Dougherty... Minerals Technologies (MTX) initiated with an Outperform at Wedbush... NextEra Energy Partners (NEP) initiated with a Buy at BofA/Merrill... PTC Therapeutics (PTCT) initiated with a Buy at BofA/Merrill... QIWI (QIWI) initiated with a Positive at Susquehanna... Quality Systems (QSII) initiated with a Buy at Topeka... Sarepta (SRPT) initiated with a Neutral at BofA/Merrill... Trinseo S.A. (TSE) initiated with a Buy at BofA/Merrill... Washington Prime Group (WPG) initiated with a Neutral at SunTrust... Zhaopin (ZPIN) initiated with a Buy at UBS.
News For ABY;ATNM;AXYS;CSG;ENPH;MTX;NEP;PTCT;QIWI;QSII;SRPT;TSE;WPG;ZPIN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
14:47 EDTSRPTDMD drug panelist confirms conflict of interest, Boston Business Journal says
Subscribe for More Information
March 27, 2015
08:24 EDTABYAbengoa announces final agreement with EIG for investments in APW-1
Subscribe for More Information
March 26, 2015
07:11 EDTMTXGabelli to hold a conference
Subscribe for More Information
March 24, 2015
11:37 EDTPTCTPTC Therapeutics CEO no longer owns company shares, TheStreet says
PTC Therapeutics CEO Stu Peltz sold the remaining 47,200 shares he owned in the company, TheStreet's Adam Feuerstein reports, citing a regulatory filing yesterday. The sale follows a stock rise in part fueled by takeover speculation, Feuerstein adds. Reference Link
07:27 EDTWPGTelsey Advisory to hold a conference
2015 Consumer Conference is being held in New York on March 24-25.
07:10 EDTATNMActinium Pharmaceuticals opens enrollment for fourth cohort in Phase I/II Trial
Actinium Pharmaceuticals announced that the company is moving forward with enrollment and treatment of additional patients in its clinical trial for acute myeloid leukemia, or AML, in patients over the age of 60. Actinium will proceed with patient screening and enrollment for the fourth cohort, who, in keeping with trial protocol, will be injected with two doses 4 to 7 days apart of the company's investigational new drug Actimab-A at a higher activity level of 2.0 ýCi/kg per dose. In the previously completed third cohort in which patients received two doses of Actimab-A at 1.5 ýCi/kg per dose two out of three Actimab-A treated patients achieved complete remission with different degrees of hematological recovery, or CRi. These responses were documented in the settings of high pre-treatment leukemia burdens of up to 80% in the bone marrow. In the second cohort treated at a lower dose level of Actimab-A of 1.0 ýCi/kg per dose, one patient achieved CRi.
March 20, 2015
16:22 EDTQSIIQuality Systems CFO Paul Holt resigns, John Stumpf named as interim CFO
On March 18, Paul Holt informed the board the he will resign as CFO of the company, effective April 12. Holt has served the company for over 15 years and is leaving to join NantHealth as its CFO. On March 19, the board appointed John Stumpf as the company's interim CFO, effective immediately upon Holt's departure from the company.
07:42 EDTATNMBioCentury to hold a conference
Subscribe for More Information
March 19, 2015
10:02 EDTQSIIOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:11 EDTPTCTPTC Therapeutics and University of Pennsylvania partner for disease research
Subscribe for More Information
March 18, 2015
16:07 EDTQSIIQuality Systems downgraded to Neutral from Outperform at RW Baird
Subscribe for More Information
09:23 EDTATNMOn The Fly: Pre-market Movers
Subscribe for More Information
07:29 EDTENPHNorthland Capital Markets to hold a conference
Subscribe for More Information
07:08 EDTATNMActinium Pharmaceuticals announces new data from Actimab-A Phase 1/2 trial
Actinium Pharmaceuticals announced the completion of the third cohort of the company's ongoing multi-center Phase 1/2 Study for Actimab-A for the treatment of newly diagnosed Acute Myeloid Leukemia, or AML, in elderly patients. Cohort 3, which included 3 additional patients, demonstrated no dose limiting toxicities in patients older than 60 and up to 87 years of age who were not eligible for currently approved therapies. Two out of three Actimab-A treated patients achieved complete remission with different degrees of hematological recovery. These responses were documented in the settings of high pre-treatment leukemia burdens of up to 88% in the bone marrow. In the previous cohort treated at a lower dose level of Actimab-A, one patient achieved CRi.
March 17, 2015
10:29 EDTCSGChambers Street Properties management to meet with JMP Securities
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use